SCHEMBL6065686

SCHEMBL6065686

Cc1cc(N2CCOCC2)ncc1Nc1ncnc(OC2CCNCC2)c1C

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 12/20 0.46
ERBB2 P04626 3/20 0.41
TTK P33981 2/20 0.38
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
LRRK2 Q5S007 1/20 0.37
TBK1 Q9UHD2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6066173 0.83 GPR119 (0.46) GPR119TTKCYP2C9
SCHEMBL390399 0.82 GPR119 (0.71) GPR119CYP2C9
SCHEMBL3170975 0.81 GPR119 (0.56) GPR119ERBB2CYP2C9
SCHEMBL6456096 0.75 GPR119 (0.54) GPR119ERBB2CYP2C9
SCHEMBL4475518 0.73 ERBB2 (0.74) ERBB2
SCHEMBL5050653 0.70 GPR119 (0.39) GPR119CYP2C9
SCHEMBL5046463 0.69 GPR119 (0.55) GPR119CYP2C9
SCHEMBL30775255 0.69 CYP2C19 (0.56) CYP2C19LRRK2TBK1
SCHEMBL12236467 0.68 HRH1 (0.43) GPR119
SCHEMBL20375579 0.68 CYP1A2 (0.44) ALDH1A1CYP1A2MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644357-A1 TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2006-04-12 EP disclosed
WO-2005007647-A1 TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2005-01-27 WO disclosed